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Abstract  
Hemolysis occurs in many hematologic and non-hematologic diseases. Extracellular hemoglobin 
(Hb) has been recognized to trigger specific pathophysiologies that are associated with adverse 
clinical outcomes in patients with hemolysis, such as acute and chronic vascular disease, 
inflammation, thrombosis and renal impairment. Among the molecular characteristics of 
extracellular Hb, translocation of the molecule into the extravascular space, oxidative and nitric 
oxide reactions, hemin release and molecular signaling effects of hemin appear to be the most 
critical. Limited clinical experience with a plasma-derived haptoglobin product in Japan and more 
recent preclinical animal studies suggest that the natural Hb and hemin scavenger proteins 
haptoglobin (Hp) and hemopexin (Hpx) have a strong potential to neutralize the adverse 
physiologic effects of Hb and hemin. This includes conditions that are as diverse as red blood cell 
transfusion, sickle cell disease, sepsis and extracorporeal circulation. This perspective reviews the 
principal mechanisms of Hb and hemin toxicity in different disease states, updates how the natural 
scavengers efficiently control these toxic moieties, and explores critical issues in the development 
of human plasma-derived Hp and Hpx as therapeutics for patients with excessive intravascular 
hemolysis. 
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Introduction 
 When hemoglobin (Hb) bursts from red blood cells due to hemolysis, the naked Hb, devoid 
of its anti-oxidant sentries that are normally available within the RBC, can wreak oxidative havoc in 
the vasculature and in exposed tissues1. To neutralize Hb and its reactive ferric protoporphyrin-IX 
group (hemin) specialized plasma scavenger proteins sequester the toxic moieties and transit them 
to compartments where heme-oxygenases can break down hemin into less toxic metabolites. 
Other molecules and reducing substances contribute to this protective physiology.  However, when 
these clearance and detoxifying systems are overwhelmed by intravascular hemolysis such as 
during sickle cell disease, blood transfusion, malaria or sepsis, Hb and hemin trigger vascular and 
organ dysfunction that leads to adverse clinical effects (Figure 1). This perspective reviews the 
mechanisms of Hb toxicity in different disease states, updates how haptoglobin (Hp) and 
hemopexin (Hpx) efficiently handle free Hb and hemin and explores why the time has come to 
consider these proteins as therapeutics in patients with excessive intravascular hemolysis. 
  
Extracellular Hb and hemin are multicomponent triggers of disease processes 
 Adverse clinical effects that are associated with excessive free Hb can be attributed to a 
number of specific structural and biochemical properties of the Hb molecule and are caused by the 
following four mutually interacting mechanisms: (1) extravascular translocation of Hb, which is a 
principal requirement that Hb and hemin can unleash their adverse reactivity in tissues; (2) nitric 
oxide and oxidative reactions; (3) release of free hemin; and (4) molecular signaling effects of 
hemin. These mechanisms are outlined in the subsequent sections and summarized in Figure 2. 
  
 Mechanism 1: Extravascular translocation of Hb 
Following hemolysis, Hb exists in a dynamic equilibrium of tetramer and αβ−subunit heterodimers, 
with a predominant dimer state at low plasma Hb concentrations. αβ-dimers are of a relatively 
small molecular size (32 kD), allowing for protein translocation and access to vulnerable anatomic 
sites (e.g. kidneys and the vascular wall). Tissue exposure to Hb is most evident in cases of overt 
hemoglobinuria following massive intravascular hemolysis, but Hb is also capable to translocate 
across endothelial barriers, entering subendothelial and peri-vascular spaces and the lymph fluid2,3.  
 
 Mechanism 2: Nitric oxide and oxidant reactions  
A second mechanism of Hb toxicity is the pro-oxidative reactivity of Hb in plasma or within tissues 
after extravasation. The Hb reactions with nitric oxide (NO) and with physiologic oxidants (e.g. 
hydrogen peroxide and lipid peroxides) are the most extensively studied. NO consumption and 
subsequent Hb oxidation occurs via two reactions: (1) NO dioxygenation of oxy-Hb that generates 
nitrate (NO3⎯) and ferric Hb (Hb-Fe3+) and (2) iron nitrosylation of deoxy-Hb which occurs by direct 
iron binding of NO to non-liganded ferrous  (Fe2+) Hb. 
 The current understanding of the biochemistry and pathophysiology of these reactions have 
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largely been derived from the study of Hb-based oxygen carriers (HBOCs) and their well-
documented adverse effects on hemodynamics4. Targeted mutagenesis of Hb aimed at limiting 
interactions with NO or chemical modifications to limit access to sites of NO bioavailability within 
the vascular wall (e.g. by chemical crosslinking of Hb into large polymers or surface decorated 
conjugates) attenuate vasoconstriction and hypertension5,6. Therefore, NO depletion by 
extracellular Hb is now a widely accepted hypothesis to explain the acute hypertensive response 
that occurs during massive hemolysis (reaching moderate to high plasma levels of free Hb) or 
during HBOC infusion6,7. Besides vasodilator depletion, another result of Hb-NO reactions might be 
the generation of ferric Hb within tissue parenchyma. Accumulation of ferric Hb within tissues may 
promote hemin release and/or transfer of hemin to other proteins/lipids with secondary toxicity 
driven by the free hemin. 
 The biochemistry of Hb reaction with peroxides has been scrutinized over the last forty 
years8. Although, the significance of these reactions for Hb and hemin driven pathophysioloigy is 
still poorly defined. The assumption that oxidative Hb side-reactions could be an important 
determinant of Hb toxicity was based on observations that peroxides are formed and released into 
the extracellular space in relatively large quantities during inflammation and ischemia-reperfusion. 
Under in vitro conditions, peroxide reaction with Hb results in the formation of ferric (Fe3+) Hb, 
higher oxidation iron species (e.g. ferryl (Fe4+) Hb), and associated radicals (Figure 2, Mechanism 
II).  It has been suggested that globin-chain free radicals are available for localized amino acid 
oxidations (e.g., within Hb) or radical transfer to non-Hb molecules (e.g. lipoproteins) 9,10. The 
proposed final outcome of these reactions is Hb self-destruction, hemin loss and globin chain 
cross-linking/precipitation which can ultimately lead to tissue damage11. It should be noted that the 
putative impact of these reactions on disease conditions is based on limited and indirect 
experimental evidence, thus, it remains uncertain whether significant quantities of ferryl (Fe4+) Hb 
and radicals are generated during in vivo hemolysis and if they contribute to disease. The only 
oxidized Hb species that can be consistently quantified in vivo are ferric (Fe3+) Hb and hemichrome, 
a structurally distorted form of ferric (Fe3+) Hb. The disparity between in vitro biochemical 
observations and in vivo findings may be due to the shifted balance between oxidation and 
reduction reactions in in vivo12. The availability of large quantities of small molecule and enzymatic 
reductants may reduce the stability of higher oxidation state Hb species and Hb-derived radicals to 
undetectable levels. Intramolecular Hb crosslinks, porphyrin-globin covalent adducts and globin 
chain amino acid oxidations have been defined as surrogate markers for ferryl (Fe4+) Hb formation. 
Such modifications were found in Hb recovered from spinal fluid after subarachnoid hemorrhage 
and from the urine, and suggested that peroxidative reactions may contribute to Hb toxicity in 
vivo13,14.  
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 Mechanism 3: Hemin release and transfer  
A third mechanism of Hb toxicity is through release of hemin from ferric (Fe3+) Hb, which is the 
main product of the oxidative reactions described in the previous section.  Hemin release allows for 
transfer of the reactive porphyrin to cell membranes or soluble plasma proteins and lipids, and it 
provides free hemin as a ligand for molecular signaling interactions. As a hydrophobic molecule it 
is unlikely that significant quantities of free, monomeric hemin can be present in plasma. Therefore, 
transferred hemin in the form of low-affinity hemin-protein (e.g. hemin-albumin) or hemin-lipid 
complexes are the most likely physiologic end products of hemin release. Depending on the 
protein or lipid environment, free iron-protoporphyrin can function as an intermediate and transform 
the recipient molecule into a reactive end product.   The most identifiable toxic end product of 
hemin release is oxidized low-density lipoprotein (oxLDL)15.  LDL oxidation and associated 
inflammatory and cytotoxic activities represents a critical example of Hb’s ability to induce vascular 
injury16,17.  
 
 Mechanism 4: Molecular signaling effects of hemin 
Hemin can selectively bind to a number of receptors, transcription factors and enzymes and 
thereby alter cell activation state, gene transcription and metabolism. The most well defined 
interaction is the binding of hemin to the transcriptional repressor Bach-1, which regulates 
transcription of heme-oxygenase 1 (HO-1) and other anti-oxidant enzymes that are essential for 
the adaptive response to enhanced intracellular hemin levels18. Hemin is also a ligand of the 
nuclear hormone receptor REV-ERB, which regulates circadian rhythm, glucose metabolism, and 
adipogenesis19. Inhibition of the proteasome by hemin and by some designed hydrophilic 
porphyrins is presently documented in biochemical assays only20,21. However, if confirmed in 
biological systems, this activity may help explain aspects of hemin toxicity. Also, activation of toll-
like receptors (TLRs) and downstream inflammatory signaling, particularly of the TLR-4 pathway, 
can be triggered by free hemin in some models22-24. 
   
 In summary, the definitive pathophysiology of extracellular Hb is dependent on timing, 
quantity and tissue localization of Hb/hemin exposure in a specific clinical condition, and may result 
from cumulative effects largely described by the four mechanisms discussed above. For example, 
systemic and to some extent pulmonary hypertension is the most apparent and readily measurable 
effect of free Hb following intravascular hemolysis.  The mechanism(s) driving acute elevations in 
blood pressure are Hb translocation into subendothelial spaces, local NO depletion within the 
vessel wall and subsequent vasoconstriction. Vascular complications of chronic and/or intermittent 
Hb exposure are likely more complicated, involving inflammation, localized oxidative reactions, 
thrombosis, vascular remodeling and renal impairment25 26-28. As outlined in the following sections, 
all four mechanisms of Hb and hemin toxicity are specifically attenuated by the natural scavenger 
proteins haptoglobin (Hp) and hemopexin (Hpx), explaining the extraordinary protective function of 
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these molecules. 
   
Biochemistry and physiology of Hb and hemin scavenger proteins 
 During mild to moderate hemolysis, a network of scavenger proteins, receptors, and 
enzymes accomplishes clearance and detoxification of extracellular Hb and hemin. The primary 
clearance pathway involves transport to the liver parenchyma or macrophages, breakdown of the 
porphyrin by the heme-oxygenases into bilirubin, carbon monoxide and iron, and recovery of the 
iron for de novo erythropoiesis. Scavenger proteins attenuate the toxicity of Hb and hemin, such 
that these potentially toxic molecules are captured and transported in an inert form. The plasma 
proteins with promising therapeutic potential are Hp and Hpx. These proteins are discussed in 
more detail in the following sections.  
 
 Haptoglobin 
Hp fundamentally changes the biochemical and physiological profile of free Hb29. When bound 
within the large molecular size Hb:Hp complex (>150 kD), Hb remains sequestered within the 
intravascular space, translocation of Hb into the kidney and across the endothelial layer appears to 
be prevented. This simple mechanism keeps potentially adverse biochemical reactions of the free 
Hb with NO and/or peroxides away from the most susceptible anatomic sites such as the vascular 
wall. Collectively, intravascular sequestration appears to be the most effective way by which Hp 
prevents Hb induced hypertension and renal damage (Figure 3).  Additionally, Hb remains 
contained within the reducing (i.e. anti-oxidant rich) environment of blood plasma until monocyte 
and macrophage clearance is complete.   
 Recent in vitro experiments suggest that Hp may also alter Hb’s oxidative reactions. Hp 
decreases the redox potential of bound ferric (Fe3+) Hb, stabilizes the higher oxidation state of Hb 
ferryl (Fe4+) Hb and prevents radical transfer to non-Hb molecules in the presence of oxidants30,31. 
The recently resolved crystal structure of the porcine Hb:Hp complex provided some structural 
basis for the protection of critical amino acids that are primary targets of globin oxidation32. As a 
result of this protection, globin oxidation with subsequent protein degradation does not occur when 
Hb is sequestered in the Hb:Hp complex33. The structural stability of the complex may prevent 
accumulation of pro-inflammatory Hb degradation products that can evade clearance by scavenger 
receptors14,34. Additionally, hemin resides firmly in the Hb:Hp complex, it cannot transfer to hemin 
acceptors, such as hemopexin, lipoproteins and albumin35. Consequently, prevention of hemin 
transfer is another essential mechanisms by which Hp protects against Hb-driven oxidation of 
membrane lipids, plasma lipoproteins, and accumulation of free hemin is prevented. 
 Genetic heterogeneity of Hp alpha-subunit composition in humans allows for the existence 
of a structural polymorphism with a dimeric Hp 1-1 (α2β2) and heterogeneous multimeric Hp 2-2 
and Hp 2-1 (α>2β>2) phenotypes36. Each Hp beta chain can bind one Hb αβ dimer, allowing for two 
binding sites in Hp 1-1 and multiple Hb dimer binding sites in Hp 2-2. The protein binding capacity 
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and the basic biochemical functions of Hp 1-1 and Hp 2-2 are equal as they relate to Hb clearance 
and detoxification (P.W. Buehler and D.J. Schaer, submitted manuscript). The molecular basis for 
the apparent association of the Hp 2-2 genotype with an enhanced risk for cardiovascular diseases 
in some high-risk patient populations remains unexplained36,37.  
 A human plasma-derived Hp product was developed by the Japanese Green Cross (now 
Benesis Corporation) and was approved in 1985 for the treatment of hemolysis due to 
extracorporeal circulation, burn injuries, and trauma with massive blood transfusions (Table 1). 
Subsequent findings of several small-scale studies indicate that Hp supplementation could prevent 
renal tubulus damage during open-heart surgery with cardiopulmonary bypass, the HELLP 
(Hemolysis Elevated Liver Enzymes Low Platelets) syndrome, and after hemolysis complicating 
endoscopic injection sclerotherapy of esophageal varices with ethanolamine-oleate (Table 1). 
Case reports and studies in a limited number of patients further support the successful use of Hp in 
patients with hemolytic anemias (i.e. thalassemia and G6PD deficiency), severe burn injury, in 
patients with hemolysis resulting from accidental AB0 incompatible RBC transfusion, and as a 
prophylaxis or treatment for hemolysis after AB0 mismatched bone marrow transplantation. The 
primary clinical criteria for Hp administration and dosing in these reports were appearance and 
reversal of hemoglobinuria, with the intent of limiting renal injury. Reported doses of Hp that were 
administered for treating acute hemolytic conditions were between ≈2g to >10g per patient, with 
dosing schedules of repeated 2g (children) or 4g (adults) boluses. The cost for the Hp therapeutic 
in Japan is currently at 540 US dollars per 2g bolus. To our knowledge there is so far no reported 
use of Hp in chronic hemolytic conditions where repeated dosing over a longer treatment period 
might be necessary to effectively suppress free plasma Hb levels.  
  
 Hemopexin  
Hpx is a hemin-binding plasma glycoprotein, which forms the second line of defense against 
intravascular hemolysis associated with hemin release from ferric (Fe3+) Hb. Multiple proteins bind 
hemin, including albumin (Kd ~10-8 M) and the lipoprotein particles LDL/HDL (Kd 10-10 M to 10-11 M). 
However, Hpx (Kd <10-13 M) is the most effective hemin binding protein that sequesters the 
porphyrin in an oxidatively inert hexacoordinate conformation in a complex with a 1:1 stoichiometry 
38
 
39-42
. The most relevant function of Hpx in plasma and tissues is likely the protection of 
susceptible lipoproteins against oxidative modifications, and to limit hemin interactions with cell 
surface receptors such as TLR-424,38,43. In hemin exposure models using the Hpx knockout mouse 
the scavenger protein demonstrated attenuation of hemin induced endothelial cell activation, vaso-
occlusion in the liver, and renal damage27,44. In the same model, data suggested that Hpx shifts 
plasma hemin to endocytosis and decomposition in hepatocytes.  
 Like Hp levels, Hpx plasma levels are generally depleted in conditions with intravascular 
hemolysis, suggesting that supplementation of the plasma protein might provide some benefit to 
patients45. However, no Hpx product is available at a quality that would allow more extensive in 
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vivo studies beyond murine models. Therefore, expanded studies with Hpx treatment may not be 
possible in the near future for larger animal models of relevant clinical conditions such as blood 
transfusion or coronary artery bypass grafting and extracorporeal circulation. 
 
 Hb and hemin scavenger receptors  
Endocytic receptors clear the biochemically inert circulating Hb:Hp and hemin:Hpx complexes from 
the circulation. In vitro and ex vivo experiments demonstrated that macrophages and peripheral 
blood monocytes, respectively, are the primary cell types that clear Hb and Hb:Hp complexes via 
binding and internalization of the scavenger receptor CD16346-49. The strong induction of CD163 by 
glucocorticoid treatment in patients with autoimmune diseases identified the Hb scavenger 
receptor as a potential therapeutic target50. Clearance of “endogenous” Hb:Hp is a rapid process 
following mild hemolysis, however, data obtained in animal models of Hb:Hp infusion or 
intravascular hemolysis with therapeutic Hp administration suggest slower clearance depending on 
the level of Hb:Hp accumulation and on the species evaluated.  We observed a long circulation 
half-life of approximately 12 hours for human and canine Hb:Hp complexes in beagle dogs with 
starting plasma concentrations of ≈150 μM (heme).   The half-life of a human Hb:Hp complex was 
approximately 16 hours at the same plasma concentration in guinea pigs (unpublished data P.W. 
Buehler and D.J. Schaer). Recent work indicates that CD163 binding specificity for Hb and the 
Hb:Hp complex, respectively, has a considerable inter-species variability, and therefore, the 
threshold for saturation of clearance mechanisms in humans and some laboratory animals might 
differ significantly51. Thus, it will be critical for early human trials to define the pharmacokinetics of 
the Hb:Hp complex at different intravascular concentrations that match conditions of single or 
repeated Hp administration during acute, intermittent and chronic hemolysis.  A similar clearance 
concept as for the Hb:Hp complex has been proposed for clearance of the hemin-hemopexin 
complex, which is bound and internalized by the low-density lipoprotein receptor-related protein 
(LRP)/CD91 on hepatocytes where hemin is degraded by HO-1 52,53.  
 Depletion of Hp and Hpx complexes via their cognate receptors during acute and chronic 
intravascular hemolysis promotes the pathophysiologic consequences outlined in Figure 1, which 
we hypothesize could be interrupted by supplementation. 
  
The role of Hb, heme and their scavenger proteins in specific human diseases 
 Sickle cell disease and other hematological diseases  
Hemolysis and vaso-occlusion are the hallmarks of sickle cells disease.  Intravascular hemolysis 
accounts for one third of red cell destruction leading to increases in plasma free Hb and hemin. 
Back in the 1960s it was recognized that plasma levels of free Hb can be as high as 25 µM during 
sickle cell crisis, with basal plasma Hb levels at 5-10 µM in sickle cell patients. Hp and Hpx levels 
were found to be depleted45. Low Hp and increased plasma free Hb levels were associated with 
increased protein carbonyl and nitrotyrosine levels in sickle cell anemia54. Clinically, uncomplicated 
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pain episodes were found to be associated with increases in plasma hemoglobin levels55,56, and 
low levels of Hp correlated with pulmonary hypertension in sickle cell anemia57. Although the 
reported plasma Hb levels in sickle cell patients are much lower than the plasma Hb levels that 
have been explored in hemodynamic studies of HBOC administration and some animal models of 
severe hemolysis, these data suggest that free Hb could be a strong pathophysiologic component 
of the vascular complications of sickle cell disease.  
 Pathophysiologic hypotheses have focused on the causal relationship between Hb 
mediated NO consumption, vascular complications and increased pulmonary artery pressure. In 
these critical studies, an increased tricuspid valve jet regurgitation (TRV) of >2.5m/s was defined 
as a surrogate marker of pulmonary hypertension in sickle cell patients. Increased TRV was found 
in 30% of patients with sickle cell disease and was well correlated with markers of hemolysis58. 
Generally, plasma Hb levels in sickle cell patients are orders of magnitude lower than the levels 
that were studied in classical experimental models of Hb or HBOC mediated NO depletion and 
vasoconstriction. However, free Hb concentrations of 6 μM impaired the vasodilatory response to 
nitroprusside infusion, suggesting that the low free plasma Hb concentrations in sickle cell patients 
could still critically limit NO bioavailability and promote vasoconstriction, platelet activation and 
coagulopathy59-61. Cumulatively, these effects were hypothesized to be causative for pulmonary 
hypertension and other vascular complications. More recently, two independent studies from 
France62 and Brazil63 employed right heart catheterization (which is the gold standard for 
diagnosing pulmonary hypertension) in addition to echocardiography for the evaluation of sickle 
cell patients. These studies confirmed that a large proportion of sickle patients have increased TRV, 
but in only 6% and 10% of the patients, respectively, pulmonary hypertension was confirmed by 
right heart catheterization. Even fewer patients (2.75% and 3.75%) had a pre-capillary pattern of 
pulmonary hypertension, which would be expected as the typical hemodynamic pattern if NO 
depletion and vasoconstriction within the pulmonary circulation were the primary pathophysiologic 
mechanism. In both studies levels of lactate dehydrogenase (LDH) were significantly higher in 
patients with confirmed pulmonary hypertension. It was therefore concluded that pulmonary 
hypertension in sickle cell patients is caused by a complex, multi-factorial pathophysiology which 
may involve NO depletion, vasoconstriction, thromboembolic vascular occlusion, left ventricular 
impairment, chronic vascular remodeling, as well as secondary hemodynamic effects caused by 
the hyperdynamic circulation that occurs in many patients with more severe or chronic anemia64,65.  
The quantitative contributions of these individual factors and the specific role of free Hb and hemin 
in the pathophysiology of vascular complication in sickle cell disease remain an important area for 
further mechanistic evaluation in clinical settings. 
 Murine models of sickle cell disease continue to provide support for a critical role of 
hemolysis and free Hb and hemin, respectively, in vaso-occlusive complications66. Sickle mice 
have intravascular hemolysis as evidenced by elevated plasma Hb, decreased Hp and Hpx, 
elevated reticulocytes and plasma bilirubin. In studies using a model of vascular stasis, induction or 
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over-expression of heme oxygenase-1 inhibits vascular stasis induced by hypoxia 67-69. 
Furthermore, infusion of hemoglobin or heme into sickle mice induced vascular stasis that could be 
inhibited by Hp or Hpx supplementation70. In the pro-oxidative environment of sickle cell anemia, 
ferrous Hb may react with NO or other oxidants to generate ferric Hb from which hemin is 
released69. In the absence of Hp and Hpx, plasma heme can interact with albumin or other plasma 
proteins and/or lipoproteins, but ultimately heme is distributed to cells in the vasculature including 
endothelial cells and leukocytes. Heme’s hydrophobicity allows it to enter cell membranes and 
activate TLR4 signaling pathways, which trigger pro-inflammatory and pro-thrombotic responses 
thereby promoting blood cell adhesion and vaso-occlusion24,70. 
  Collectively, epidemiologic and experimental data support a concept whereby substitution 
of Hp and/or Hpx could attenuate or prevent complications associated with accelerated 
intravascular hemolysis in sickle cell disease.  
 
 There are many other hematologic diseases in which hemolysis constitutes a primary 
disease process (e.g. thalassemia, paroxysmal nocturnal hemoglobinuria (PNH), glucose-6-
phosphate dehydrogenase deficiency) or a secondary phenomenon (e.g. hemolytic uremic 
syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)). Although the contribution of free 
Hb and hemin toxicity to disease outcome has not been explored in this wider arena of hemolytic 
disorders, the broader availability of Hp and Hpx will provide us the required tools to systematically 
explore the therapeutic potential of Hb/hemin neutralization in these multi-factorial diseases. 
 
 Blood transfusion   
Retrospective data analyses suggest that transfusion of older stored blood (approaching 42 days) 
results in increased morbidity and mortality when compared to newer blood71. Increased morbidity 
has typically been associated with immune suppression, infection, cardiovascular complications 
and acute/chronic kidney injury. One of the most essential consequences of the so-called “RBC 
storage lesion” is related to reduced deformability, enhanced in vivo fragility and susceptibility of 
RBCs to attack by components of the immune system. These changes may be accompanied by 
increased hemolysis of older storage RBC. 
 Although the clinical impact of blood storage duration on clinical outcome remains 
controversial, numerous models have been developed to evaluate the effects of hemolysis and Hb 
toxicity72-75. Guinea pigs subjected to massive transfusion (the equivalent of >10 units) of 
maximally stored guinea pig blood demonstrated increased plasma Hb concentrations over a 24-
hour period, which resulted from post-transfusion hemolysis76.  This was associated with increased 
hemoglobinuria, acute renal failure, hypertension and vascular injury. Hp co-infusion with older 
storage blood resulted in attenuation of adverse renal and vascular effects to resemble that of new 
blood transfusion.   These observations are supported by several studies that suggest blood 
transfusion in mice, rats and sheep are associated with increased blood pressure, NO depletion, 
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and increased plasma Hb concentrations74,75,77. Hb related transfusion complications in humans 
have also been associated with ABO mismatch and massive transfusion (>10 units/24 hours).  
 Clinically, Hp has been used to treat adverse transfusion outcomes in Japan, and the 
primary reported outcome of therapeutic Hp treatment appears to be prevention of renal tubular 
injury (Table 1). 
   
 Sepsis and Malaria   
Hemolysis can also occur during severe bacterial infection and sepsis, and depletion of Hpx has 
been associated with more severe disease and fatal outcome78. Within these complex disease 
processes, hemin could act as an activator of innate immunity via pattern recognition receptor 
activation (e.g. TLR-4), via synergistic effects with microbial products or endogenous pro-
inflammatory ligands (e.g. HMGB1), or via peroxidative tissue damage24,79,80. Studies on mice 
suggested that the net effect of free hemin in polymicrobial sepsis could be detrimental and that 
neutralization of hemin by Hpx administration ameliorates this effect78.  
 The protective action of Hpx in sepsis may involve the control of excessive hemin 
peroxidative activity, inhibition of innate immunity receptor interactions and redirection of free 
hemin away from susceptible tissues towards clearance in the liver. Restriction of hemin-iron 
access by Hb and hemin scavenger proteins could be another protective mechanism against 
severe infections by some bacterial strains81,82. The in vivo activity of Hpx may also involve Hpx 
activities that are independent of its primary hemin scavenger function. The outcome of such 
activities has been noted as anti-inflammatory in some instances (e.g. Hpx attenuates 
inflammatory cytokine secretion by LPS stimulated macrophages83), whereas impaired bacterial 
clearance was found as a consequence of suppressed neutrophil migration in other mouse 
studies84. At this point, it is unknown whether such non-hemin related effects of Hpx are an 
inherent activity of the protein itself or side effects caused by impurities or degradation products in 
some preparations of plasma-derived Hpx85.  
 In mouse models of malaria, Hb/hemin driven oxidative damage and NO depletion were 
linked to the evolution of cerebral malaria86. However, although we may suspect that this 
pathophysiology could be attenuated by Hp and/or Hpx treatment, the efficacy of scavenger 
proteins has not yet been tested for this specific condition. 
 
 Conclusion: Is there an unmet need for scavenger protein-based therapeutics? 
Multiple hematologic and non-hematologic disease states are associated with RBC lysis and the 
adverse effects of free Hb and hemin potentially complicate clinical disease outcome. There is 
currently no viable therapy designed to attenuate the adverse effects of free Hb and hemin.  
Intuitively, replacement or supraphysiologic dosing of Hp and/or Hpx to match acute or ongoing 
hemolysis may be of therapeutic benefit by attenuating many of the pathophysiologies that we 
discuss in this perspective, and a number of clinical situations where Hb contributes to acute (e.g. 
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acute kidney injury) and chronic (e.g. vascular remodeling) sequelae.  Plasma purified Hp has 
been marketed in Japan since 1985 with primary indications for use in conjunction with 
extracorporeal circulation, massive transfusion and thermal injury.  The primary therapeutic effect 
in these disease states is protection of kidneys from Hb induced toxicity87. Thus far no therapeutic 
experience exists for Hpx in a clinical setting.  However, several US and EU based pharmaceutical 
companies have commenced development projects to fractionate Hp and Hpx from human plasma 
for use as therapeutics during hemolytic diseases. In 2011 a human plasma-derived Hp was given 
orphan drug status for the treatment of sickle cell disease in the EU. However, to date preclinical 
proof of concept for Hp and Hpx have been studied within a general context of hemolysis and Hb 
driven pathophysiology and not with intent to treat a specific disease. Within most countries 
drugs/biologics are approved based on indication specific improvement in disease outcome and 
acceptable safety.  Therefore, rational selection of potential indications, dose schedules and 
clinical trial design to achieve measurable outcomes and acceptable safety profiles will be critical 
for the concepts presented here to successfully progress towards improved patient care. These 
and other questions will pose exciting basic science, clinical and regulatory challenges in 
development process of Hb/hemin scavenging therapeutics.       
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Table 1.  Literature cited clinical use of Haptoglobin in Japan 
 
Clinical Condition Subjects/Controls Haptoglobin 
dose 
Primary finding 
(intention of treatment) 
Reference 
Cardiopulmonary 
bypass surgery 
 
 
CABG in a patient 
with β-thalassemia 
and severe 
hemolysis 
16/21 
 
14/0 
 
Single case report 
 
6 grams 
 
4 grams 
Prevention of acute 
renal failure 
 
87
 
88
 
 
89
 
Peripheral blood 
stem cell transplant 
Single case report 3 grams Prevention of acute 
renal failure 
 
90
 
Hemolytic 
transfusion reaction 
Single case report 6 grams Prevention of acute 
renal failure 
 
91
 
Massive transfusion 16/34 6 grams Undetermined benefit 
 
92
 
Extracorporeal 
circulation 
10/10 6 grams Prevention of acute 
renal failure 
 
93
 
HELLP syndrome 
(Hemolysis Elevated 
Liver enzymes Low 
Platelets) 
17/17 3 grams Prevention of acute 
renal failure 
 
94
 
ABO incompatible 
bone marrow 
transplantation  
Two patient case 
reports 
11 grams Prevention of acute 
renal failure 
 
95
 
Thermal injury Single case report 
(repeated, large 
dose therapy) 
>20 grams  
 
 
 
 
Improved outcome  
 
 
 
Prevention of 
hemoglobinuria and 
acute renal failure 
 
96
 
 
 
97
 
 
Glucose-6-
phosphate 
dehydrogenase 
deficiency 
Single patient case 
report (24 month 
old boy) 
8.5 grams Prevention of 
hemoglobinuria 
 
98
 
Adult patent ductus 
arteriosus, coil 
embolization 
Single patient case 
report 
45 grams Prevention of 
hemoglobinuria 
 
99
 
 
 
 
Figure Legends 
 
Figure 1: Schematic summary of the Hb clearance compartments and the main acute and 
chronic pathologies that can be associated with intravascular hemolysis. The availability of 
the Hb and hemin scavenger proteins haptoglobin (Hp) and hemopexin (Hpx) shifts the physiologic 
balance from tissue damage towards protection.  
 
 
Figure 2: Schematic summary of the principal mechanisms of hemoglobin toxicity and 
protection by the plasma scavenger proteins haptoglobin and hemopexin. 
 
 
Figure 3.  Haptoglobin sequestration of hemoglobin: Guinea pigs were infused with stroma 
free Hb (peak plasma Hb concentration 150 μM heme) and after 10 min a treatment group of 
animals was infused with human plasma derived haptoglobin (Hp) to match an equimolar Hb:Hp 
concentration. (A) Mean arterial blood pressure response before and after Hp treatment.  (B) 
Unbound plasma Hb (red) prior to Hp administration and after Hp administration. The left shift in 
the chromatogram indicates the large molecular size Hb:Hp complex with approximately 90% Hp 
bound and 10% unbound Hb.  (C) Hemoglobinuria following Hb infusion (150 μM heme) -Hp (left) 
and +Hp (right).  (D) Iron deposition (brown staining) in normal kidney renal cortex (left), Hb 
infusion (middle) and Hb infusion + Hp (right). (E) Heme oxygenase-1 expression in kidneys after 
24 hours following Hb exposure with and without Hp infusion (left), densitometry is shown to the 
right of the HO-1 western blot.  All data are presented as mean +/- SEM. 
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